Hepatitis B virus and renal transplantation

Nephron

Volumn 90, Issue 3, 2002, Pages 241-251

  Fabrizi, Fabrizio ^a   Martin, Paul ^b   Ponticelli, Claudio ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE;

DIALYSIS; DISEASE COURSE; DISEASE SEVERITY; DISEASE TRANSMISSION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER DISEASE; LIVER DYSFUNCTION; LIVER HISTOLOGY; MEDICAL ASSESSMENT; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SUPERINFECTION; TREATMENT OUTCOME; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DISEASE PROGRESSION; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS C ANTIBODIES; HEPATITIS D; HUMANS; KIDNEY TRANSPLANTATION; SUPERINFECTION; SURVIVAL RATE; TISSUE DONORS;

EID: 0036184529     PISSN: 00282766     EISSN: None     Source Type: Journal    
DOI: 10.1159/000049058     Document Type: Review

References (91)

1. Impact of hepatitis on renal transplantation
2. sAg-positive patients
3. Liver disease in recipients of long-functioning renal allografts
4. Renal transplant recipients and chronic liver disease: Statistical evaluation of predisposing factors
5. Liver disease after renal transplantation
6. Absence of hepatitis delta virus infection in chronic hemodialysis and kidney transplant patients in France
7. Co-infection by hepatitis B virus and hepatitis C virus in renal transplantation: Morbidity and mortality in 1,098 patients
8. The impact of donor and recipient hepatitis B surface antigen status on liver disease and survival in renal transplant recipients
9. Impact of hepatitis B and C virus on kidney transplantation outcome
10. santi-genemia on long-term patient survival and causes of death after renal transplantation
11. Prevalence and clinical course of hepatitis B and hepatitis C liver disease in ciclosporin-treated renal allograft recipients
12. Hepatitis B liver disease in cyclosporine-treated renal allograft recipients
13. The impact of renal transplantation on the course of hepatitis B liver disease
14. The transplanted kidney as a source of hepatitis B infection
15. The transmission of hepatitis B by renal transplantation
16. sAg negative recipients
17. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response
18. Natural history of hepatitis B virus infection in renal transplant recipients - A fifteen-year follow-up
19. Reactivation of hepatitis B after transplantation operations
20. Occurrence and management of hepatitis B virus reactivation following kidney transplantation
21. Redevelopment of hepatitis B surface antigen after renal transplantation
22. Hepatitis B virus and hepatitis B-related viral infection in renal transplant recipients: A prospective study of 90 patients
23. Chronic viral hepatitis and the management of chronic renal failure
24. Hepatitis B surface antigen gene expression is regulated by sex steroids and glucocorticoids in transgenic mice
25. Hepatitis B virus DNA contains a glucocorticoid response element
26. Corticosteroids stimulate hepatitis B virus DNA, mRNA, and protein production in a stable expression system
27. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro
28. Modulation of WHV infection and disease with cyclosporine A and dexamethasone
29. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy
30. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: Report of a prospective study
31. Liver transplantation for viral hepatitis: Current status
32. eantigen and/or HBV DNA positive
33. sAg-negative patients: Molecular characterization and clinical implications
34. Hepatitis B virus persistence after recovery from acute viral hepatitis
35. Presence of hepatitis B and C viral genomes in US blood donors as detected by polymerase chain reaction amplification
36. Members of the Scientific Section Coordinating Committee: Antibodies to hepatitis B core antigen and the infectivity of the blood supply
37. cAb(+), HBIgM(-) organ donors
38. Use of hepatitis B core antibody-positive multi-organ donors
39. Biological consequences of interactions between hepatitis B virus and human nonhepatic cellular genomes
40. Risks of transplanting kidneys from hepatitis B surface antigen-negative, hepatitis B core antibody-positive donors
41. Use of renal allografts from donors positive for hepatitis B core antibody confers minimal risk for subsequent development of clinical hepatitis B virus disease
42. Can hepatitis B core antibody positive livers be used safely for transplantation: Hepatitis B virus detection in the liver of individuals who are B core antibody positive
43. Hepatitis B disease in dialysis and transplant patients
44. Renal transplantation in asymptomatic carriers of hepatitis B surface antigen
45. Renal transplantation is not contraindicated in asymptomatic carriers of hepatitis B surface antigen
46. Observations of decreased glutamic-oxaloacetic transaminase (SGOT) activity in azotemic patients
47. Influence of hepatitis C viremia upon serum aminotransferase activity in chronic dialysis patients
48. Decreased aspartate aminotransferase (SGOT) activity in serum of uremic patients
49. Impact of decreased serum transaminase levels on the evaluation of viral hepatitis in hemodialysis patients
50. Lowered aminotransferase activity in patients with chronic renal failure on conservative therapy
51. Value of liver biopsy in the evaluation and management of chronic liver disease in renal transplant recipients
52. Is renal transplantation involved in post-transplantation liver disease?
53. The clinical and pathological course of hepatitis B liver disease in renal transplant recipients
54. Hepatitis in renal transplant recipients
55. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis
56. Chronic hepatitis B in asymptomatic homosexual men with antibodies to human immunodeficiency virus
57. The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection
58. Variability in the morphological spectrum and clinical outcome of chronic liver disease in hepatitis B-positive and B-negative renal transplant recipients
59. Clinicopathological course of hepatitis B infection in surface antigen carriers following living-related renal transplantation
60. sAg-positive renal transplant patients treated with cyclosporin and steroids
61. Hepatitis B and renal transplantation
62. Fulminant hepatitis in renal transplant recipients: The role of delta agent
63. Prognostic significance of hepatitis B surface antigenemia in cadaveric renal transplant patients
64. The influence of hepatitis B infection on the outcome of renal allotransplantation
65. Liver diseases and hepatic complications in renal transplant patients
66. Successful transplantation in patients positive for hepatitis B antigen
67. The effect of hepatitis B antigenemia on long-term success and hepatic disease in renal transplant recipients
68. santigenemia on patient survival after renal transplantation
69. How to manage the dialysis patient with chronic viral hepatitis who is considered for renal transplantation
70. Association of graft survival with host response to hepatitis B infection in patients with kidney transplant
71. Impact of donor hepatitis B antigenemia on renal allograft in hepatitis B recipients
72. Chronic hepatitis in kidney allograft recipients
73. sAg-positive chronic active hepatitis
74. Withdrawal of azathioprine in renal transplant patients with chronic active hepatitis: Is it wise or not?
75. Reduction of azathioprine in renal transplant patients with chronic hepatitis
76. Imminent liver failure in a hepatitis B positive renal allograft recipient: Successful therapy with interferon-alpha
77. Recombinant leucocyte interferon A induces steroid-resistant acute vascular rejection episodes in renal transplant recipients
78. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C
79. Effectiveness of adenine arabinoside 5′-monophosphate in kidney transplant recipients with chronic active hepatitis B
80. Treatment of hepatitis B virus replication by ganciclovir in kidney transplant patients
81. Long-term treatment of chronic hepatitis B with oral ganciclovir in two kidney transplant recipients
82. Occurrence and management of hepatitis B virus reactivation following kidney transplantation
83. A preliminary trial of lamivudine for chronic hepatitis B infection
84. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis
85. Successful use of lamivudine for severe acute hepatitis B virus infection in a cardiac transplant recipient
86. Lamivudine inhibits hepatitis B virus replication in kidney graft recipients
87. Treatment of chronic hepatitis B with lamivudine in renal transplant recipients
88. Efficacy and safety of lamivudine on replication of recurrent hepatitis B after cadaveric renal transplantation
89. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient
90. Hepatitis-B-virus resistance to lamividine given for recurrent infection after orthotopic liver transplantation
91. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC)